Phoenix Local Business
Wednesday, July 8, 2015
PCSK9 Inhibitors vs. The Guidelines
(MedPage Today) -- A return to LDL targets may be one consequence of the new drug class
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment